Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2009

Lu DY, Nassar A, Siddiqui MT. High-grade urothelial carcinoma: comparison of SurePath liquid-based processing with cytospin processing. Diagn Cytopathol. 2009;37(1):16-20.

Lin Z, Yemelyanova AV, Gambhira R, Jagu S, Meyers C, Kirnbauer R, et al. Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2. Am J Pathol. 2009;174(1):136-43.

Ma X, Norsworthy K, Kundu N, Rodgers WH, Gimotty PA, Goloubeva O, et al. CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther. 2009;8(3):490-8.

2008

Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008;100(11):815-25.

Diaz-Meco MT, Moscat J. Akt regulation and lung cancer: a novel role and mechanism of action for the tumor suppressor Par-4. Cell Cycle. 2008;7(18):2817-20.

McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell. 2008;133(6):994-1005.

Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2008;111(3):1101-9.

Rutgers EJ, Pusztai L, Bernards R. Are short-term or long-term recurrence rates more important in breast cancer screening? Ann Intern Med. 2008;149(5):357; author reply 357-8.

Siddiqui MT, Cohen C, Nassar A. Detecting high-grade cervical disease on ASC-H cytology: role of BD ProEx C and Digene Hybrid Capture II HPV DNA testing. Am J Clin Pathol. 2008;130(5):765-70.

Heller KN, Arrey F, Steinherz P, Portlock C, Chadburn A, Kelly K, et al. Patients with Epstein Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1. Int J Cancer. 2008;123(12):2824-31.